Pages that link to "Q37426527"
Jump to navigation
Jump to search
The following pages link to Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients (Q37426527):
Displayed 44 items.
- Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance (Q26740219) (← links)
- Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications (Q26777408) (← links)
- Era of direct acting antivirals in chronic hepatitis C: Who will benefit? (Q26777506) (← links)
- HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy (Q26782405) (← links)
- Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance (Q26783056) (← links)
- Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance (Q27469038) (← links)
- State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization (Q28079102) (← links)
- Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control (Q28082128) (← links)
- Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay (Q28548426) (← links)
- High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods (Q28652352) (← links)
- Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data (Q31042796) (← links)
- Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China (Q33672648) (← links)
- Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan. (Q35154587) (← links)
- Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia (Q35735285) (← links)
- Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6 (Q35917596) (← links)
- Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study (Q36100521) (← links)
- Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients (Q36182240) (← links)
- Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran (Q36278496) (← links)
- Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. (Q36292486) (← links)
- High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study (Q36651317) (← links)
- New treatments for chronic hepatitis C: an overview for paediatricians (Q38282842) (← links)
- Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals (Q38779980) (← links)
- Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. (Q38888859) (← links)
- Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden (Q39020651) (← links)
- Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. (Q40419604) (← links)
- Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. (Q40784280) (← links)
- Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C (Q41521289) (← links)
- Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study (Q42183060) (← links)
- Antiviral treatment of hepatitis C. (Q42207125) (← links)
- Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients. (Q44104489) (← links)
- Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. (Q45324124) (← links)
- Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. (Q45324912) (← links)
- Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs (Q47121746) (← links)
- Analysis of naturally occurring resistance-associated variants to NS3/4A protein inhibitors, NS5A protein inhibitors and NS5B polymerase inhibitors in patients with chronic hepatitis C. (Q47314419) (← links)
- Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C. (Q47397635) (← links)
- Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. (Q55379857) (← links)
- Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem? (Q57491238) (← links)
- Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank (Q58564271) (← links)
- Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients (Q58780610) (← links)
- Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus (Q59126211) (← links)
- Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection (Q61816060) (← links)
- Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes (Q64064438) (← links)
- Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide (Q90398259) (← links)
- The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients (Q92876947) (← links)